182 related articles for article (PubMed ID: 15475931)
1. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.
Shoman N; Klassen S; McFadden A; Bickis MG; Torlakovic E; Chibbar R
Mod Pathol; 2005 Feb; 18(2):250-9. PubMed ID: 15475931
[TBL] [Abstract][Full Text] [Related]
2. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
4. [Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression].
Liu C; Zhou S; Ke CS; Li NP; Wu RL
Ai Zheng; 2007 Sep; 26(9):929-36. PubMed ID: 17927847
[TBL] [Abstract][Full Text] [Related]
5. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
[TBL] [Abstract][Full Text] [Related]
8. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer.
Depowski PL; Rosenthal SI; Ross JS
Mod Pathol; 2001 Jul; 14(7):672-6. PubMed ID: 11454999
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
12. A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
Kerr DA; Wittliff JL
Horm Cancer; 2011 Oct; 2(5):261-71. PubMed ID: 21826535
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
[TBL] [Abstract][Full Text] [Related]
15. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
16. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
17. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
19. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.
Kok M; Holm-Wigerup C; Hauptmann M; Michalides R; Stål O; Linn S; Landberg G
J Natl Cancer Inst; 2009 Dec; 101(24):1725-9. PubMed ID: 19940281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
